FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233314911> ?p ?o ?g. }

• W4233314911 abstract "Patients with paroxysmal supraventricular tachycardia frequently present to the Emergency Department. Where vagal manoeuvres fail, the two most commonly used drugs are adenosine and calcium channel antagonists. Both are known to be effective but both have a significant side-effect profile.To examine the relative effects of adenosine and calcium channel antagonists and, if possible, to determine which is most appropriate for the management of supraventricular tachycardia.Studies were identified from The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, Issue 2, 2010, MEDLINE (1966 to May Week 1 2010) and EMBASE (1980 to 2010 week 19). The searches were originally run in June 2006 and updated and re-run in May 2010. Bibliographies of identified studies were also examined. No language restrictions were applied.Randomised trials comparing adenosine and a calcium channel antagonist in patients of any age with supraventricular tachycardia, where one of the defined outcomes was reported. Outcomes of interest were: reversion rate, mortality, time to reversion, rate of relapse, major and minor adverse events, length of hospital stay and patient satisfaction.Two authors independently checked the results of searches to identify relevant studies. Dichotomous outcomes were reported as Peto Odds ratios and continuous outcomes as weighted mean differences.A total of ten trials were identified (two new trials were identified through the updated search in May 2010), all of which used verapamil as the calcium antagonist. In the pooled analysis there was no significant difference in reversion rate between the two drugs. Time to reversion was slower for verapamil than adenosine in all studies that reported this outcome, but the data were not suitable for combining. Relapse rates were higher for adenosine compared with verapamil (OR 0.25, 95% CI 0.07 to 0.99. P=0.05). Minor adverse events such as nausea, chest tightness, shortness of breath and headache were reported much more frequently in patients treated with adenosine with 10.8 % of patients reporting at least one of these events, compared with 0.6% of those treated with verapamil (OR 0.15, 95% CI 0.09 to 0.26, P<0.001). Hypotension was reported exclusively in the verapamil treatment group (4/214), and occurred in none of the patients treated with adenosine (OR 10.8, 95% CI 1.46 to 80.22, P=0.02).Adenosine and verapamil are both effective treatments for supraventricular tachycardia in the majority of patients. There is a high incidence of minor but unpleasant side effects and a greater risk of relapse in patients treated with adenosine while some patients treated with verapamil may develop significant hypotension. Patients should be fully informed of these risks prior to treatment." @default.
• W4233314911 created "2022-05-12" @default.
• W4233314911 creator A5002654482 @default.
• W4233314911 creator A5075702002 @default.
• W4233314911 date "2012-02-15" @default.
• W4233314911 modified "2023-10-14" @default.
• W4233314911 title "Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults" @default.
• W4233314911 cites W1974433402 @default.
• W4233314911 cites W1978812120 @default.
• W4233314911 cites W1979813254 @default.
• W4233314911 cites W1989892019 @default.
• W4233314911 cites W1994748041 @default.
• W4233314911 cites W1995071804 @default.
• W4233314911 cites W2000442546 @default.
• W4233314911 cites W2011375554 @default.
• W4233314911 cites W2037271760 @default.
• W4233314911 cites W2040258776 @default.
• W4233314911 cites W2056118617 @default.
• W4233314911 cites W2057806510 @default.
• W4233314911 cites W2064149664 @default.
• W4233314911 cites W2067245155 @default.
• W4233314911 cites W2082209926 @default.
• W4233314911 cites W2083038215 @default.
• W4233314911 cites W2086637755 @default.
• W4233314911 cites W2088011157 @default.
• W4233314911 cites W2152350310 @default.
• W4233314911 cites W2165473148 @default.
• W4233314911 doi "https://doi.org/10.1002/14651858.cd005154.pub3" @default.
• W4233314911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22336809" @default.
• W4233314911 hasPublicationYear "2012" @default.
• W4233314911 type Work @default.
• W4233314911 citedByCount "5" @default.
• W4233314911 countsByYear W42333149112015 @default.
• W4233314911 countsByYear W42333149112016 @default.
• W4233314911 countsByYear W42333149112017 @default.
• W4233314911 countsByYear W42333149112020 @default.
• W4233314911 countsByYear W42333149112022 @default.
• W4233314911 crossrefType "reference-entry" @default.
• W4233314911 hasAuthorship W4233314911A5002654482 @default.
• W4233314911 hasAuthorship W4233314911A5075702002 @default.
• W4233314911 hasConcept C126322002 @default.
• W4233314911 hasConcept C142724271 @default.
• W4233314911 hasConcept C156957248 @default.
• W4233314911 hasConcept C164705383 @default.
• W4233314911 hasConcept C197934379 @default.
• W4233314911 hasConcept C204787440 @default.
• W4233314911 hasConcept C27081682 @default.
• W4233314911 hasConcept C2776478404 @default.
• W4233314911 hasConcept C2776934708 @default.
• W4233314911 hasConcept C2777022698 @default.
• W4233314911 hasConcept C2780283014 @default.
• W4233314911 hasConcept C42219234 @default.
• W4233314911 hasConcept C519063684 @default.
• W4233314911 hasConcept C71924100 @default.
• W4233314911 hasConcept C95190672 @default.
• W4233314911 hasConceptScore W4233314911C126322002 @default.
• W4233314911 hasConceptScore W4233314911C142724271 @default.
• W4233314911 hasConceptScore W4233314911C156957248 @default.
• W4233314911 hasConceptScore W4233314911C164705383 @default.
• W4233314911 hasConceptScore W4233314911C197934379 @default.
• W4233314911 hasConceptScore W4233314911C204787440 @default.
• W4233314911 hasConceptScore W4233314911C27081682 @default.
• W4233314911 hasConceptScore W4233314911C2776478404 @default.
• W4233314911 hasConceptScore W4233314911C2776934708 @default.
• W4233314911 hasConceptScore W4233314911C2777022698 @default.
• W4233314911 hasConceptScore W4233314911C2780283014 @default.
• W4233314911 hasConceptScore W4233314911C42219234 @default.
• W4233314911 hasConceptScore W4233314911C519063684 @default.
• W4233314911 hasConceptScore W4233314911C71924100 @default.
• W4233314911 hasConceptScore W4233314911C95190672 @default.
• W4233314911 hasLocation W42333149111 @default.
• W4233314911 hasLocation W42333149112 @default.
• W4233314911 hasOpenAccess W4233314911 @default.
• W4233314911 hasPrimaryLocation W42333149111 @default.
• W4233314911 hasRelatedWork W2025923048 @default.
• W4233314911 hasRelatedWork W2036423321 @default.
• W4233314911 hasRelatedWork W2059524123 @default.
• W4233314911 hasRelatedWork W2082830426 @default.
• W4233314911 hasRelatedWork W2359825457 @default.
• W4233314911 hasRelatedWork W2374509921 @default.
• W4233314911 hasRelatedWork W2374685850 @default.
• W4233314911 hasRelatedWork W2421627522 @default.
• W4233314911 hasRelatedWork W2903486660 @default.
• W4233314911 hasRelatedWork W2323886323 @default.
• W4233314911 isParatext "false" @default.
• W4233314911 isRetracted "false" @default.
• W4233314911 workType "reference-entry" @default.